Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
«Новые» молекулы в составе рациональных комбинаций антигипертензивных препаратов: вопросы выбора - Журнал Системные Гипертензии Том 12, №4
«Новые» молекулы в составе рациональных комбинаций антигипертензивных препаратов: вопросы выбора
Кисляк О.А., Червякова Ю.Б. «Новые» молекулы в составе рациональных комбинаций антигипертензивных препаратов: вопросы выбора. Системные гипертензии. 2015; 12 (4): 42–45.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье обсуждаются факторы, определяющие выбор антигипертензивных препаратов, в частности блокаторов рецепторов ангиотензина (БРА) и тиазидных диуретиков (ТД). Приводятся данные об особенностях 8-го сартана в линейке БРА азилсартана медоксомила, препарата Эдарби, его отличиях от других сартанов. Среди основных свойств Эдарби, которые могут определить его выбор для лечения пациентов с артериальной гипертензией, называются значительная прочность связывания данного БРА с АТ1-рецептором и длительность его действия, а также особые свойства, способствующие повышению чувствительности тканей к инсулину. Обсуждается целесообразность создания фиксированных комбинаций азилсартана медоксомина с ТД хлорталидоном, препарата Эдарби Кло.
Ключевые слова: артериальная гипертензия, блокаторы рецепторов ангиотензина, азилсартан медоксомил, тиазидные диуретики, хлорталидон.
Key words: arterial hypertension, angiotensin receptor blocker therapy, azilsartan medoxomil, thiazide diuretics, chlorthalidone.
Ключевые слова: артериальная гипертензия, блокаторы рецепторов ангиотензина, азилсартан медоксомил, тиазидные диуретики, хлорталидон.
________________________________________________
Key words: arterial hypertension, angiotensin receptor blocker therapy, azilsartan medoxomil, thiazide diuretics, chlorthalidone.
Полный текст
Список литературы
1. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 7 (3): 5–26. / Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr). Sistemnye gipertenzii. 2010; 7 (3): 5–26. [in Russian]
2. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013; 31: 1281–357.
3. Диагностика и лечение артериальной гипертензии. Клинические рекомендации, разработанные по поручению МЗ РФ. М., 2013. http://www.gipertonik.ru/clinical_recommendations / Diagnostika i lechenie arterial'noi gipertenzii. Klinicheskie rekomendatsii, razrabotannye po porucheniiu MZ RF. M., 2013. http://www.gipertonik.ru/clinical_recommendations [in Russian]
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
5. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20. doi:10.1001/jama.2013.284427.
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55 (2): 399–407.
7. Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag 2011; 7: 605–22.
8. Kajiya T, Ho C, Wang J et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011; 29: 2476–83.
9. Takagi H, Mizuno Y, Niwa M et al for the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertension Research advance online publication, 10 October 2013; doi:10.1038/hr.2013.142
10. Bakris GL, Domenic Sica D, Weber M et al. The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatoryand Clinic Blood Pressure. J Clin Hypertens 2011; 13 (2): 81–8.
11. Кобалава Ж.Д., Виллевальде С.В. Азилсартана медоксомил: новые возможности в лечении артериальной гипертонии. Фармакологические свойства. doi: http://dx.doi.org/10.18565/cardio.2014.12.57-62 / Kobalava Zh.D., Villeval'de S.V.. Azilsartana medoksomil: novye vozmozhnosti v lechenii arterial'noi gipertonii. Farmakologicheskie svoistva. doi: http://dx.doi.org/10.18565/cardio.2014.12.57-62 [in Russian]
12. Остроумова О.Д. Азилсартан – новый представитель класса блокаторов рецепторов к ангиотензину II. doi: http://dx.doi.org/10.18565/cardio.2014.9.65-71 / Ostroumova O.D. Azilsartan – novyi predstavitel' klassa blokatorov retseptorov k angiotenzinu II. doi: http://dx.doi.org/10.18565/cardio.2014.9.65-71 [in Russian]
13. Barrios V, Escobar С. Which thiazide to choose as add-on therapy for hypertension? Integrated Blood Pressure Control 2014; 7: 35–47.
14. Roush GC, Buddharaju V, Ernst ME, Holford TR. Chlorthalidone: Mechanisms of Action and Effect on Cardiovascular Events. Curr Hypertens Rep; 2013; 15: 514–21. doi 10.1007/s11906-013-0372–1.
15. SHEP Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265 (24): 3255–64.
16. Wright JrJT, Probstfield JL, Cushman WC et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169 (9): 832–42.
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
18. Weber MA. The ALLHAT report: A case of information and misinformation. J Clin Hypertens 2003; 5: 9–13.
19. Clinicaltrials.gov. Efficacy and safety of azilsartan medoxomil co-administered with chlorthalidone in participants with essential hypertension. Study NCT00591773. http:// clinicaltrials.gov/ct2/show/NCT00591773?term=NCT00591773&rank=1. Accessed December 13, 2011.
20. Sica D, Bakris GL, White WB et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14: 284–92.
21. Cheng JWM. Azilsartan/chlorthalidone combination therapyfor blood pressure controlIntegrated Blood Pressure Control 2013: 6: 39–48.
22. Cushman WC et al. Hypertension 2012; 60: 310–8.
23. Bakris G et al. Am J Med 2012; 125: 1229. e1-1229.e10.
2. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013; 31: 1281–357.
3. Diagnostika i lechenie arterial'noi gipertenzii. Klinicheskie rekomendatsii, razrabotannye po porucheniiu MZ RF. M., 2013. http://www.gipertonik.ru/clinical_recommendations [in Russian]
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
5. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20. doi:10.1001/jama.2013.284427.
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55 (2): 399–407.
7. Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag 2011; 7: 605–22.
8. Kajiya T, Ho C, Wang J et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011; 29: 2476–83.
9. Takagi H, Mizuno Y, Niwa M et al for the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertension Research advance online publication, 10 October 2013; doi:10.1038/hr.2013.142
10. Bakris GL, Domenic Sica D, Weber M et al. The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatoryand Clinic Blood Pressure. J Clin Hypertens 2011; 13 (2): 81–8.
11. Kobalava Zh.D., Villeval'de S.V.. Azilsartana medoksomil: novye vozmozhnosti v lechenii arterial'noi gipertonii. Farmakologicheskie svoistva. doi: http://dx.doi.org/10.18565/cardio.2014.12.57-62 [in Russian]
12. Ostroumova O.D. Azilsartan – novyi predstavitel' klassa blokatorov retseptorov k angiotenzinu II. doi: http://dx.doi.org/10.18565/cardio.2014.9.65-71 [in Russian]
13. Barrios V, Escobar С. Which thiazide to choose as add-on therapy for hypertension? Integrated Blood Pressure Control 2014; 7: 35–47.
14. Roush GC, Buddharaju V, Ernst ME, Holford TR. Chlorthalidone: Mechanisms of Action and Effect on Cardiovascular Events. Curr Hypertens Rep; 2013; 15: 514–21. doi 10.1007/s11906-013-0372–1.
15. SHEP Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265 (24): 3255–64.
16. Wright JrJT, Probstfield JL, Cushman WC et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169 (9): 832–42.
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
18. Weber MA. The ALLHAT report: A case of information and misinformation. J Clin Hypertens 2003; 5: 9–13.
19. Clinicaltrials.gov. Efficacy and safety of azilsartan medoxomil co-administered with chlorthalidone in participants with essential hypertension. Study NCT00591773. http:// clinicaltrials.gov/ct2/show/NCT00591773?term=NCT00591773&rank=1. Accessed December 13, 2011.
20. Sica D, Bakris GL, White WB et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14: 284–92.
21. Cheng JWM. Azilsartan/chlorthalidone combination therapyfor blood pressure controlIntegrated Blood Pressure Control 2013: 6: 39–48.
22. Cushman WC et al. Hypertension 2012; 60: 310–8.
23. Bakris G et al. Am J Med 2012; 125: 1229. e1-1229.e10.
2. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013; 31: 1281–357.
3. Диагностика и лечение артериальной гипертензии. Клинические рекомендации, разработанные по поручению МЗ РФ. М., 2013. http://www.gipertonik.ru/clinical_recommendations / Diagnostika i lechenie arterial'noi gipertenzii. Klinicheskie rekomendatsii, razrabotannye po porucheniiu MZ RF. M., 2013. http://www.gipertonik.ru/clinical_recommendations [in Russian]
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
5. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20. doi:10.1001/jama.2013.284427.
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55 (2): 399–407.
7. Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag 2011; 7: 605–22.
8. Kajiya T, Ho C, Wang J et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011; 29: 2476–83.
9. Takagi H, Mizuno Y, Niwa M et al for the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertension Research advance online publication, 10 October 2013; doi:10.1038/hr.2013.142
10. Bakris GL, Domenic Sica D, Weber M et al. The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatoryand Clinic Blood Pressure. J Clin Hypertens 2011; 13 (2): 81–8.
11. Кобалава Ж.Д., Виллевальде С.В. Азилсартана медоксомил: новые возможности в лечении артериальной гипертонии. Фармакологические свойства. doi: http://dx.doi.org/10.18565/cardio.2014.12.57-62 / Kobalava Zh.D., Villeval'de S.V.. Azilsartana medoksomil: novye vozmozhnosti v lechenii arterial'noi gipertonii. Farmakologicheskie svoistva. doi: http://dx.doi.org/10.18565/cardio.2014.12.57-62 [in Russian]
12. Остроумова О.Д. Азилсартан – новый представитель класса блокаторов рецепторов к ангиотензину II. doi: http://dx.doi.org/10.18565/cardio.2014.9.65-71 / Ostroumova O.D. Azilsartan – novyi predstavitel' klassa blokatorov retseptorov k angiotenzinu II. doi: http://dx.doi.org/10.18565/cardio.2014.9.65-71 [in Russian]
13. Barrios V, Escobar С. Which thiazide to choose as add-on therapy for hypertension? Integrated Blood Pressure Control 2014; 7: 35–47.
14. Roush GC, Buddharaju V, Ernst ME, Holford TR. Chlorthalidone: Mechanisms of Action and Effect on Cardiovascular Events. Curr Hypertens Rep; 2013; 15: 514–21. doi 10.1007/s11906-013-0372–1.
15. SHEP Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265 (24): 3255–64.
16. Wright JrJT, Probstfield JL, Cushman WC et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169 (9): 832–42.
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
18. Weber MA. The ALLHAT report: A case of information and misinformation. J Clin Hypertens 2003; 5: 9–13.
19. Clinicaltrials.gov. Efficacy and safety of azilsartan medoxomil co-administered with chlorthalidone in participants with essential hypertension. Study NCT00591773. http:// clinicaltrials.gov/ct2/show/NCT00591773?term=NCT00591773&rank=1. Accessed December 13, 2011.
20. Sica D, Bakris GL, White WB et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14: 284–92.
21. Cheng JWM. Azilsartan/chlorthalidone combination therapyfor blood pressure controlIntegrated Blood Pressure Control 2013: 6: 39–48.
22. Cushman WC et al. Hypertension 2012; 60: 310–8.
23. Bakris G et al. Am J Med 2012; 125: 1229. e1-1229.e10.
________________________________________________
2. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013; 31: 1281–357.
3. Diagnostika i lechenie arterial'noi gipertenzii. Klinicheskie rekomendatsii, razrabotannye po porucheniiu MZ RF. M., 2013. http://www.gipertonik.ru/clinical_recommendations [in Russian]
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
5. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20. doi:10.1001/jama.2013.284427.
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55 (2): 399–407.
7. Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag 2011; 7: 605–22.
8. Kajiya T, Ho C, Wang J et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011; 29: 2476–83.
9. Takagi H, Mizuno Y, Niwa M et al for the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertension Research advance online publication, 10 October 2013; doi:10.1038/hr.2013.142
10. Bakris GL, Domenic Sica D, Weber M et al. The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatoryand Clinic Blood Pressure. J Clin Hypertens 2011; 13 (2): 81–8.
11. Kobalava Zh.D., Villeval'de S.V.. Azilsartana medoksomil: novye vozmozhnosti v lechenii arterial'noi gipertonii. Farmakologicheskie svoistva. doi: http://dx.doi.org/10.18565/cardio.2014.12.57-62 [in Russian]
12. Ostroumova O.D. Azilsartan – novyi predstavitel' klassa blokatorov retseptorov k angiotenzinu II. doi: http://dx.doi.org/10.18565/cardio.2014.9.65-71 [in Russian]
13. Barrios V, Escobar С. Which thiazide to choose as add-on therapy for hypertension? Integrated Blood Pressure Control 2014; 7: 35–47.
14. Roush GC, Buddharaju V, Ernst ME, Holford TR. Chlorthalidone: Mechanisms of Action and Effect on Cardiovascular Events. Curr Hypertens Rep; 2013; 15: 514–21. doi 10.1007/s11906-013-0372–1.
15. SHEP Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265 (24): 3255–64.
16. Wright JrJT, Probstfield JL, Cushman WC et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169 (9): 832–42.
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
18. Weber MA. The ALLHAT report: A case of information and misinformation. J Clin Hypertens 2003; 5: 9–13.
19. Clinicaltrials.gov. Efficacy and safety of azilsartan medoxomil co-administered with chlorthalidone in participants with essential hypertension. Study NCT00591773. http:// clinicaltrials.gov/ct2/show/NCT00591773?term=NCT00591773&rank=1. Accessed December 13, 2011.
20. Sica D, Bakris GL, White WB et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14: 284–92.
21. Cheng JWM. Azilsartan/chlorthalidone combination therapyfor blood pressure controlIntegrated Blood Pressure Control 2013: 6: 39–48.
22. Cushman WC et al. Hypertension 2012; 60: 310–8.
23. Bakris G et al. Am J Med 2012; 125: 1229. e1-1229.e10.
Авторы
О.А.Кисляк*, Ю.Б.Червякова
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*kisliakoa@mail.ru
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*kisliakoa@mail.ru
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*kisliakoa@mail.ru
________________________________________________
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*kisliakoa@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.